Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Global biological sample collections from tuberculosis studies: a scoping review.

Author information

Affiliations

  • 1. Centre for International Health, University of Otago, Dunedin, New Zealand.
      Authors
    • Adolph C 1
    • Hill PC 1
    (2 authors)
  • 2. South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
      Authors
    • Mendelsohn SC 2
    (1 author)
  • 3. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, and Tuberculosis Imaging Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD, USA.
      Authors
    • Via LE 3
    (1 author)
  • 4. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
      Authors
    • Martinez L 4
    (1 author)
  • 5. Centre for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA; Centre for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
      Authors
    • Lindestam Arlehamn CS 5
    (1 author)
    • Show all (7)

The Lancet. Microbe, 21 Oct 2026, :101287
https://doi.org/10.1016/j.lanmic.2025.101287 PMID: 41448215 

Review

Abstract 

Progress in tuberculosis vaccine development is hindered by the incomplete understanding of protective immunity and other disease mechanisms. An interconnected network of sample biorepositories from tuberculosis studies could help to address these gaps. To assess the feasibility of such a resource, we conducted a scoping review of tuberculosis observational studies and vaccine clinical trials. The included studies collected at least one biological sample from tuberculosis cases, contacts, or controls and had more than 100 participants. We contacted the corresponding authors of these studies to determine the sample availability and interest in interconnected biorepositories. For the period 2014-24, we identified 104 observational studies and 18 vaccine trials that collected biological samples from 35 075 tuberculosis cases, 39 450 contacts or controls, and 45 628 trial participants across 43 countries. The commonly collected samples were blood, human genomic DNA, RNA, and sputum. Interest among the contacted investigators was high. Interconnected sample biorepositories could facilitate large-scale investigations and accelerate progress towards tuberculosis vaccine development.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.lanmic.2025.101287

References 

Articles referenced by this article (33)

Show 10 more references (10 of 33)

Citations & impact 

This article has not been cited yet.

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

    Funding 

    Funders who supported this work.

    Division of Intramural Research

      Gates Foundation (1)

      • Grant ID: INV-058406

        Loading publications

      National Institute of Allergy and Infectious Diseases

        National Institutes of Health

          • Annotations
            In abstract (8)
          • Save
          • Claim to ORCID